Suppurative cholangitis

Summary

Suppurative cholangitis (MONDO:0001928) is a disease. A subtype of cholangitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	suppurative cholangitis
Mondo ID	MONDO:0001928
DOID	DOID:14269
ICD-11	32799822
NCIT	C35336
SNOMED CT	69850007
UMLS	C0267924
MedGen	82766
Is cancer (heuristic)	no

Also known as: suppurative cholangitis

Disease family

This is a subtype of cholangitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › bile duct disorder › non-neoplastic bile duct disorder › cholangitis › suppurative cholangitis

Related subtypes (8): ascending cholangitis, acute cholangitis, pericholangitis, cholecystitis, chronic cholangitis, sclerosing cholangitis, primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome, autoimmune cholangitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.